BACKGROUND: Acute kidney injury (AKI) is a critical condition for kidney and other remote organs, including the lung. However, available treatments for AKI are limited. In this study, we explored the effect of adipose-derived mesenchymal cells on a mouse model of AKI. METHODS: Adipose-derived mesenchymal cells were isolated from mouse subcutaneous and peritoneal adipose tissue by digestion with collagenase type I. The left renal artery and vein of C57BL/6 mice were clamped for 45 min to induce ischemia and were injected with the adipose-derived mesenchymal cells [1 × 10(5) cells/0.2 ml phosphate-buffered saline (PBS)] or 0.2 ml PBS via the tail vein on days 0, 1, and 2. RESULTS: The adipose-derived mesenchymal cells had stem-cell surface markers and multilineage differentiating potentials. Administered adipose-derived mesenchymal cells homed primarily into lung. Interestingly, repeated administration of adipose-derived mesenchymal cells reduced acute tubular necrosis and interstitial macrophage infiltration in the injured kidney, accompanied with reduced cytokine and chemokine expression. CONCLUSION: Adipose-derived mesenchymal cells can be used as cell-based therapy for ischemic kidney injury.
BACKGROUND:Acute kidney injury (AKI) is a critical condition for kidney and other remote organs, including the lung. However, available treatments for AKI are limited. In this study, we explored the effect of adipose-derived mesenchymal cells on a mouse model of AKI. METHODS: Adipose-derived mesenchymal cells were isolated from mouse subcutaneous and peritoneal adipose tissue by digestion with collagenase type I. The left renal artery and vein of C57BL/6 mice were clamped for 45 min to induce ischemia and were injected with the adipose-derived mesenchymal cells [1 × 10(5) cells/0.2 ml phosphate-buffered saline (PBS)] or 0.2 ml PBS via the tail vein on days 0, 1, and 2. RESULTS: The adipose-derived mesenchymal cells had stem-cell surface markers and multilineage differentiating potentials. Administered adipose-derived mesenchymal cells homed primarily into lung. Interestingly, repeated administration of adipose-derived mesenchymal cells reduced acute tubular necrosis and interstitial macrophage infiltration in the injured kidney, accompanied with reduced cytokine and chemokine expression. CONCLUSION: Adipose-derived mesenchymal cells can be used as cell-based therapy for ischemic kidney injury.
Authors: Ryang Hwa Lee; Min Jeong Seo; Andrey A Pulin; Carl A Gregory; Joni Ylostalo; Darwin J Prockop Journal: Blood Date: 2008-09-25 Impact factor: 22.113
Authors: Manchang Liu; Yideng Liang; Srinivasulu Chigurupati; Justin D Lathia; Mikhail Pletnikov; Zhaoli Sun; Michael Crow; Christopher A Ross; Mark P Mattson; Hamid Rabb Journal: J Am Soc Nephrol Date: 2008-04-02 Impact factor: 10.121
Authors: Christina L Klein; Tom S Hoke; Wen-Feng Fang; Christopher J Altmann; Ivor S Douglas; Sarah Faubel Journal: Kidney Int Date: 2008-07-02 Impact factor: 10.612
Authors: Jun Tashiro; Sharon J Elliot; David J Gerth; Xiaomei Xia; Simone Pereira-Simon; Rhea Choi; Paola Catanuto; Shahriar Shahzeidi; Rebecca L Toonkel; Rahil H Shah; Fadi El Salem; Marilyn K Glassberg Journal: Transl Res Date: 2015-09-18 Impact factor: 7.012
Authors: Flavia Ps Freitas; Marcella L Porto; Camilla P Tranhago; Rogerio Piontkowski; Emilio C Miguel; Thaiz Bar Miguel; Jorge L Martins; Kyria S Nascimento; Camille M Balarini; Benildo S Cavada; Silvana S Meyrelles; Elisardo C Vasquez; Agata L Gava Journal: Am J Transl Res Date: 2015-12-15 Impact factor: 4.060